System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Epublish 14 citations

PubMed: 39595200 DOI: 10.3390/biomedicines12112636

Disease Modifying Monoclonal Antibodies and Symptomatic Pharmacological Treatment for Alzheimer's Disease.

Biomedicines 12(11)

Authors: Xiaoming Qi, Damir Nizamutdinov, Song Stephen Yi, Erxi Wu, Jason H Huang

Affiliations

  • Department of Neurology, Baylor Scott & White Health, Temple, TX 78508, USA.
  • Department of Neurosurgery, Neuroscience Institute, Baylor Scott & White Health, Temple, TX 78508, USA.
  • Department of Neurosurgery, Neuroscience Institute, Baylor Scott & White Health, Temple, TX 78508, USA. Department of Neurosurgery, Baylor College of Medicine, Temple, TX 76508, USA. College of Medicine, Texas A&M University, College Station, TX 77843, USA. College of Irma Lerma Rangel College of Pharmacy, Texas A&M University, College Station, TX 77843, USA. LIVESTRONG Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX 78712, USA.
  • Department of Neurosurgery, Baylor College of Medicine, Temple, TX 76508, USA.
  • College of Medicine, Texas A&M University, College Station, TX 77843, USA.

Abstract

Alzheimer's Disease (AD) is an irreversible, progressive syndrome characterized by neurocognitive impairment. Two neuropathological features seen in AD are extracellular amyloid plaques consisting of amyloid beta1-40 and 1-42, and intracellular neurofibrillary tangles (NFTs). For decades, neuroscience research has heavily focused on seeking to understand the primary mechanism of AD and searching for pharmacological approaches for the treatment of dementia. Three monoclonal antibodies that act against amyloid beta-aducanumab, lecanemab, and donanemab-have been approved by the Food and Drug Administration (FDA) for the treatment of mild cognitive impairment and mild AD, in addition to medications for cognitive symptom management such as acetylcholinesterase inhibitors and the N-methyl-D-aspartate (NMDA) antagonist. Further trials should focus on the combination of therapies targeting amyloid plaques and tau pathology.

MeSH

Plaque, Amyloid, Antibodies, Alzheimer Disease, Cognitive Dysfunction, Cognition Disorders, Antibodies, Monoclonal, Therapeutics, Amyloid

Cited by